{"name":"Osivax","slug":"osivax","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Afluria Quad","genericName":"Afluria Quad","slug":"afluria-quad","indication":"Seasonal influenza prevention in adults and children","status":"phase_2"}]}],"pipeline":[{"name":"Afluria Quad","genericName":"Afluria Quad","slug":"afluria-quad","phase":"phase_2","mechanism":"Afluria Quad is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four strains of influenza virus.","indications":["Seasonal influenza prevention in adults and children"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOZjltVWpNSHg0cHBZQTZGU0k5VklwOENQME9vWWFzaGtIQm1YTVBvYW1FdWtZYUdhWHJkMGdkZ1NiUURoM0xZSWdSZG9QdF9mOWZPVnM5NUtsVHptQ1Y4Z0RDNG5vdWZnMUhuUWhtWXVVSG41d0ZlZ0t0STcxZkttaXNDWURKWkpPN0V2d1FMZW0teWx5ZXpiRmdn?oc=5","date":"2025-08-29","type":"pipeline","source":"C&EN","summary":"BARDA provides Osivax with $19.5 million for universal flu vaccine - C&EN","headline":"BARDA provides Osivax with $19.5 million for universal flu vaccine - C&EN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQSGlqcHNIRngwSXRMZzZPSE5wLTFOU0RiRnU1RHFPWkpRWVJERHFVdllMV21OZWlQd2RzSVdybUhRWlJmWnduREg5LTYzT19YY01tZWFXNEpCbloxa25aQU13OW5ERF81TUNMMWxRZHROMnJMT3dSNmpkZy1JVUVKdlBKanBIeUdXdEJOY3hyMXhBSGJ2WU9wM0xMYVdwbG9DWWc?oc=5","date":"2025-07-10","type":"trial","source":"PharmaTimes","summary":"Osivax publishes phase 2a results supporting dual flu vaccine approach - PharmaTimes","headline":"Osivax publishes phase 2a results supporting dual flu vaccine approach","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-03-12","type":"pipeline","source":"Pulse 2.0","summary":"Osivax: €10 Million Raised For Developing Vaccines To Provide Protection Against Respiratory Viruses - Pulse 2.0","headline":"Osivax: €10 Million Raised For Developing Vaccines To Provide Protection Against Respiratory Viruses - Pulse 2.0","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPWW1ueTB4Yjl5TFhPY2FKcUxqLTFRaFJMVXNXWjdyQUJaZ2pTOG81X21qRXR2S2szdHRxaUtlRXVPSEc3MWt3cUVFamQxQVhSbGhCRTdRVi1BemI1amtWRnA5TzVqNFU0TmUzNDJpZE84TGV0MFJBLXNGdlRMRkFRclBxdjBkdjVn?oc=5","date":"2025-03-06","type":"pipeline","source":"The Pharma Letter","summary":"Osivax secures strategic funding from Meiji Seika - The Pharma Letter","headline":"Osivax secures strategic funding from Meiji Seika","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxQUER6dW9DOUUyZXFObnlUcHowYjhxRGptTWZaVWdGWHFUQ0NUOEJER1AyZHBGVDZqNlZreE5ETHl2dklRYTA0MFRyXzczSjAwYm5zY1V5elE0TnM5ZEp3TG90OTBqRFlXZHItQlpQN2QtRGJNZTFYbDhPTS1vVXh3MjFDRkVSa3JZUXJoZ1M3MmhPYUFuclhTZVRqZXVDMUMteV9oNldOQV9NN2NKNDljcVFZRnVyMHBKVW1KajhrZHVnaWN3M21pUnhxV3VhQS1PUHBUZTE5UlRSd3R2TVNWT016M05tYzl3dExV?oc=5","date":"2025-03-04","type":"pipeline","source":"Business Wire","summary":"Osivax Secures Strategic Funding to Accelerate the Development of its Influenza Vaccine Candidates - Business Wire","headline":"Osivax Secures Strategic Funding to Accelerate the Development of its Influenza Vaccine Candidates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNWTU3YzVRQkhWQzZHMlFCeDBwZlR1WkdJUWw0QWdZT3pEcTQ2NDllcWlpZWh0R3A2MUZjbzlJSlVncGNuTm1uejI1NlJvV19wc1Y5OVc1ZVdldkJ2MGx4ajFFOHBoX0k2VHV0aVJKT2tla2dWd0Q2NnBIbFF2TkFhMWsxNUNEemk1R2Rub1JoYXU2Zw?oc=5","date":"2024-11-14","type":"trial","source":"PharmaTimes","summary":"Osivax begins phase 2a booster trial for influenza vaccine - PharmaTimes","headline":"Osivax begins phase 2a booster trial for influenza vaccine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOYzBzNTlyOFRleHN4ei16Z1NVR2NXa2lhb0F0WDM3ZV8zZl9hRV9JRkZ2UURzLS1HYmx2MjJHOHhPWDlpb0F6NEFvSC1QZHpmbjU4Sl83c21vZGRMazBoTzdKdlVLaE8zYjR2UDJ0bUdKeEMzdUpjcG1udWIwOVE2djZJM3hxdG1nUTY1ZGNmVmt6ZXdYelBIRFJ5UFdZaHFPaTZjMDNB?oc=5","date":"2022-09-07","type":"deal","source":"BioSpace","summary":"Global Roundup: Zealand Pharma and Novo Nordisk Headline Cross-Continental Collaborations - BioSpace","headline":"Global Roundup: Zealand Pharma and Novo Nordisk Headline Cross-Continental Collaborations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQbnFfbDU2Vlc0ZW9BcnItOVEta2p2eVBmM3FaaFFERG5CS0tRd2JBd2ZtWXNOd0lXMEZYNG55LS1SaF82T3ltWDFnV2JVQmQzODJjT0RHSGdDOS1LcGJzemZzV2I2cjI1NnVEV0FFSFBKQXhVT05xZlhQQmxWMGNzTjYyOUtnUHczRGdCaTlCQjdjZ3FpbTZyaXZDdktWeWVKc09feVNtbVc5bEVGS09PR29ZSk52Z0t3UkhvbHFDZ2UtWHh3YklxYk45RUo3c1UtOUVZX0FILVozU1MzZTFfREZaYmo1dw?oc=5","date":"2022-08-31","type":"pipeline","source":"PR Newswire","summary":"Influenza Pipeline Looks Promising as 100+ Companies Working in the Domain, Assesses DelveInsight - PR Newswire","headline":"Influenza Pipeline Looks Promising as 100+ Companies Working in the Domain, Assesses DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxORHllSVNYWjNOeG5INzJlajdyTkFmczhCNmN6bG5LVmdaY0JhMU5iYUp0RzlmMGZTMHNSQTV1MnVoLWJIbndMcXVmb0loZmg2bzdlZ0hzNzhrbzRhd2hDaHl5UXBfMy1HNXdzTlNQUUpZaTdZWWUzaEQzaWRadEN6eTJ4ZUFieF9MMGNvelBzbkEtTWd1Ym5URHdDZzVFWnZXaHRWMi1kOVVVZW5uRURXWjdn?oc=5","date":"2020-05-07","type":"pipeline","source":"StartUs Insights","summary":"5 Top Emerging Vaccine Startups Impacting The Pharma Industry - StartUs Insights","headline":"5 Top Emerging Vaccine Startups Impacting The Pharma Industry","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}